Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of ($1.19) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Alnylam Pharmaceuticals Stock Down 0.4 %
Alnylam Pharmaceuticals stock opened at $169.34 on Tuesday. The company’s 50-day moving average price is $183.67 and its 200-day moving average price is $179.31. Alnylam Pharmaceuticals has a twelve month low of $148.10 and a twelve month high of $227.91. The company has a market cap of $21.25 billion, a PE ratio of -40.90 and a beta of 0.43.
Insider Buying and Selling
In related news, Director Michael W. Bonney sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total transaction of $5,850,000.00. Following the completion of the transaction, the director now owns 16,029 shares in the company, valued at approximately $3,125,655. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.40% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of analysts have recently weighed in on ALNY shares. HC Wainwright restated a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, December 15th. Piper Sandler upped their price target on shares of Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an “overweight” rating in a report on Thursday, December 14th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, January 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday. Finally, Wells Fargo & Company started coverage on shares of Alnylam Pharmaceuticals in a report on Friday, December 8th. They set an “equal weight” rating and a $171.00 price target on the stock. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $230.95.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- How to Invest in Mining Stocks
- 3 attractive stocks that insiders are buying
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- The 3 Best Fintech Stocks to Buy Now
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.